Corient Private Wealth LLC Purchases 21,383 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Corient Private Wealth LLC increased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 86.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,249 shares of the biopharmaceutical company's stock after acquiring an additional 21,383 shares during the period. Corient Private Wealth LLC's holdings in Royalty Pharma were worth $1,180,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in RPRX. Keene & Associates Inc. raised its holdings in Royalty Pharma by 1.9% in the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock valued at $495,000 after acquiring an additional 370 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Royalty Pharma by 31.3% in the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 376 shares during the period. Sanctuary Advisors LLC boosted its position in Royalty Pharma by 0.9% in the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock valued at $1,068,000 after buying an additional 388 shares during the period. Arizona State Retirement System boosted its stake in shares of Royalty Pharma by 0.5% in the 4th quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company's stock valued at $2,822,000 after buying an additional 537 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Royalty Pharma by 31.4% in the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 590 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Remove Ads

Royalty Pharma Stock Performance

RPRX stock traded down $0.28 during trading on Friday, hitting $31.37. 4,077,104 shares of the company's stock traded hands, compared to its average volume of 3,103,202. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The stock has a fifty day moving average price of $32.44 and a two-hundred day moving average price of $28.86. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $18.08 billion, a price-to-earnings ratio of 21.63, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, equities analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.81%. The ex-dividend date was Friday, February 21st. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's payout ratio is 60.69%.

Analysts Set New Price Targets

Several analysts have recently weighed in on RPRX shares. Citigroup restated a "buy" rating on shares of Royalty Pharma in a research report on Friday. TD Cowen upgraded shares of Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.